Medical Treatments for Prostate CancerThere are many different medical treatments for prostate cancer that involve the clinical care of a healthcare professional. These treatments include expectant therapy, surgery, radiation therapy, hormone therapy, and chemotherapy. Expectant therapy is to carefully observe and monitor the prostate cancer. Because prostate cancer cells often spread very slowly, many older men who have the disease may not need more extensive treatment. However, expectant therapy usually includes routine physician examinations, including digital rectal exams and PSA tests. The different types of surgery for prostate cancer are radical prostatectomy - an open-surgery procedure in which the entire prostate gland and surrounding tissue are removed. Transurethral resection of the prostate (TURP) - surgery to remove part of the prostate gland that surrounds the urethra. Cryosurgery - this procedure involves killing the cancer cells by freezing them with a small metal tool placed in the tumor. Side effects of prostate cancer surgery include incontinence and impotence. Incontinence is the inability to control urine and may result in dribbling of urine, especially immediately after surgery. Normal control usually returns within weeks or months after surgery. Impotence is the inability to achieve an erection. For a month, or so, after surgery, most men are not able to get an erection. Eventually, approximately 40 to 60 percent of men will be able to get an erection sufficient for sexual intercourse, but without ejaculation of semen, since removal of the prostate gland prevents that process.Radiation therapy uses high energy rays to kill or shrink cancer cells, and to decrease their ability to divide. Radiation is often used to treat prostate cancer that is still confined to the prostate gland, or has spread only to nearby tissue. If the disease is advanced, radiation may be used to reduce the size of the tumor and to provide relief from symptoms. Possible side effects of radiation for prostate cancer may include diarrhea, with or without blood in the stool, and colitis, problems associated with urination, a degree of impotence (inability to get an erection), which may occur within two years of radiation therapy. The goal of hormone therapy is to lower the level of male hormones in the body, particularly testosterone. Hormone therapy does not cure the cancer, and is often used to treat persons whose cancer has spread or recurred after treatment. Produced mainly in the testicles, testosterone causes prostate cancer cells to grow. Thus, reduced testosterone levels can make the prostate cancer shrink and become less active. Most studies show that hormone therapy works better if it is started early. Chemotherapy is the use of powerful, anti-cancer medications to kill cancer cells.. Hospitalization may be needed to monitor treatment and chemotherapy's side effects. Common side effects of chemotherapy include: nausea and vomiting, hair loss, anemia, reduced ability of blood to clot, mouth sores, increased likelihood of developing infections, fatigue. Most side effects disappear once treatment is stopped. |
| 8 cancer hhv prostate |
|
Reply: Antibody levels against BK virus and prostate, kidney and Using immunohistochemistry, 10 consecutive prostate cancer tissue sections . The seroepidemiology of HHV-8/KSHV in a large population of black cancer Cancer News Content: HHV-8 present in immunocompetent Patient Advocacy, Psycho-Social Issues, New Cancer Drugs, Prostate Cancer Until recently, primary HHV-8 infection had been described only in HHV-8 (KSHV) does not establish latency in prostate cancer cell lines. BACKGROUND: HHV-8 is a new herpesvirus found in lesions of Kaposi s sarcoma and some lymphoproliferative diseases. More recently, a report stated that HHV-8 seropositivity linked with prostate cancer The findings are the first to link HHV-8 seropositivity with prostate cancer. Still, senior author Dr. Frank J. Jenkins, from the University of Pittsburgh, University of Pittsburgh GSPH IDM Faculty-Frank Jenkins The role of a newly discovered human herpesvirus, HHV-8, in development and pathogenesis of human herpesvirus 8 (HHV-8) among men with prostate cancer. Cancer Spectrum: pp. 1257 Randomized Trial of Clodronate for Metastatic Prostate Cancer 1330) studied the association between HHV-8 seropositivity and transfusion history among Plasma Antibodies against Chlamydia trachomatis, Human A significant inverse association was observed between HHV-8 antibody seropositivity and prostate cancer (OR, 0.70; 95% CI, 0.52-0.95). Plasma Antibodies against Chlamydia trachomatis, Human ORs and 95% CIs of prostate cancer by C. trachomatis, HPV, and HHV-8 serostatus in 691 matched pairs nested in the HPFS, 1993-2000 NEJM -- Antibodies against Human Herpesvirus 8 in Black South Background Infection with human herpesvirus 8 (HHV-8) has been and Human Herpesvirus Type 8 in Relation to Prostate Cancer: A Prospective Study. Hoffman et al., HHV-8 in Prostate Cancer 8 and prostate cancer, we determined the prevalence of HHV-8 seropositivity among prostate cancer case and control subjects in the United States and University of Chicago Press - HHV-8 and Prostate Cancer - 10.1086 To investigate a possible association between human herpesvirus 8 (HHVâ8) and prostate cancer, we evaluated HHVâ8 seroprevalence in 2 caseâcontrol studies. Elevated seroprevalence of human herpesvirus 8 among men with Among 138 Tobago men with prostate cancer, HHV-8 seroprevalence was HHV-8 seropositivity is elevated among men with prostate cancer compared with No serological evidence of association between prostate cancer and An association between prostate cancer and herpes simplex virus type 2 (HSV-2) or Kaposi sarcoma-associated herpesvirus/human herpesvirus type 8 (HHV-8) HHV-8 (KSHV) does not establish latency in prostate cancer cell lines Our results argue against the in-. volvement of HHV-8 in prostate cancer and for a limited tissue tropism of HHV-8. Prostate. 33:286â288, 1997. Herpesviruses: HHV-8 The situation with HHV-8 and prostate cancer is presently unclear. Although some studies have linked HHV-8 seropositivity with prostate cancer, HHV-8 (KSHV) does not establish latency in prostate cancer cell lines. Our results argue against the involvement of HHV-8 in prostate cancer and for a limited tissue tropism of HHV-8. Review References:, None. Notes:, None HHV-8 (KSHV) does not establish latency in prostate cancer cell lines. Our results argue against the involvement of HHV-8 in prostate cancer and for a limited tissue tropism of HHV-8. MeSH Terms: Human Herpesvirus 8 in the Prostate Glands of Men with Kaposi's Five of nine HHV-8-seropositive men had HHV-8 DNA detected in prostate tissue by JNCI J Natl Cancer Inst 93: 194-202 Abstract Full Text; Vieira, J., Human Herpesvirus 8 in the Prostate Glands of Men with Kaposi's Five of nine HHV-8-seropositive men had HHV-8 DNA detected in prostate tissue by Herpesvirus Type 8 in Relation to Prostate Cancer: A Prospective Study. |
| 8 cancer hhv prostate |
|
cancerous prostate surgery cancer comer gary prostate cancer holistic prostate treatment causes of prostate cancer |